CoChat

Enoxaparin and Aspirin Compared With Aspirin Alone to Prevent Placenta-Mediated Pregnancy Complications: A Randomized Controlled Trial

Haddad, Bassam, Winer, Norbert, Chitrit, Yvon, Houfflin-Debarge, Véronique, Chauleur, Céline, Bages, Karine, Tsatsaris, Vassilis, Benachi, Alexandra, Bretelle, Florence, Gris, Jean-Christophe, Bastuji-Garin, Sylvie, for the Heparin-Preeclampsia (HEPEPE) Trial Investigators · 2016 · Obstetrics & Gynecology

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To evaluate whether daily enoxaparin, added to low-dose aspirin, started before 14 weeks of gestation reduces placenta-mediated complications in pregnant women with previous severe preeclampsia diagnosed before 34 weeks of gestation. METHODS: In this open-label multicenter randomized trial, we enrolled consenting pregnant women with previous severe preeclampsia diagnosed before 34 weeks of gestation, gestational age at randomization of 7–13 weeks, singleton pregnancy, and no plan for anticoagulation. Eligible patients were randomly assigned to a one-to-one ratio to receive daily either 4,000 international units enoxaparin plus 100 mg aspirin or 100 mg aspirin alone. Randomization was done by a web-based randomization system. The primary composite outcome comprised maternal death, perinatal death, preeclampsia, small for gestational age (less than the 10th percentile), and placental abruption. A sample size of 232 women equally divided into two groups was needed to detect a significant reduction in primary outcome from 55% in the aspirin group to 36.7% in the enoxaparin-aspirin group (α: 0.05, β: 0.8, two-sided). RESULTS: Between November 14, 2009, and February 21, 2015, 257 participants were enrolled. Baseline demographic and clinical factors were similar between groups. Eight women were excluded after randomization (six in the enoxaparin–aspirin group and two in the aspirin group), leaving 124 participants assigned to enoxaparin–aspirin and 125 to aspirin. Five participants were lost to follow-up (two in the enoxaparin–aspirin group and three in the aspirin group). There was no significant difference between the groups in the primary outcome: enoxaparin–aspirin 42 of 122 (34.4%) compared with aspirin alone 50 of 122 (41%) (relative risk 0.84, 95% confidence interval 0.61–1.16, P=.29). The occurrence of complications did not differ between the two groups. CONCLUSION: Antepartum prophylactic enoxaparin does not significantly reduce placenta-mediated complications in women receiving low-dose aspirin for previous severe preeclampsia diagnosed before 34 weeks of gestation. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT00986765.

Overview

Integrity signals

Registry

Crossref · 10.1097/aog.0000000000001673

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 34 references

Research works printed but not linked: 1

  1. 2013, Hypertension in pregnancy. American College of Obstetricians and Gynecologists, Obstet Gynecol, 122, 1122

Cited by

See all 92

Metadata

Authors
Haddad, B., Winer, N., Chitrit, Y., Houfflin-Debarge, V., Chauleur, C., Bages, K., Tsatsaris, V., Benachi, A., Bretelle, F., Gris, J.-C., Bastuji-Garin, S., & for the Heparin-Preeclampsia (HEPEPE) Trial Investigators
Affiliations
Université Paris-Est Créteil (FR)
Venue
Obstetrics & Gynecology
Published
2016-11
Volume
128
Issue
5
Pages
1053-1063
ISSN
0029-7844 (ISSN-L)
OpenAlex
W2531818013
Cited by
92
References
34
Citations by year
2026: 2 · 2025: 11 · 2024: 9 · 2023: 6 · 2022: 12 · 2021: 10 · 2020: 9 · 2019: 10 · 2018: 7 · 2017: 15 · 2016: 1
FWCI
14.18
Type
journal article
Language
en
Open access
closed
Locations
  • Obstetrics and Gynecology (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Topics
  • Health Sciences › Medicine › Obstetrics and Gynecology › Pregnancy and preeclampsia studies
  • Health Sciences › Medicine › Clinical Neurology › Neurological Complications and Syndromes
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Maternal and fetal healthcare
Keywords
enoxaparin, low-dose aspirin, placenta-mediated pregnancy complications, preeclampsia recurrence, placental abruption, small for gestational age, maternal mortality, perinatal mortality, anticoagulation in pregnancy, thromboprophylaxis, pregnancy loss prevention
MeSH terms
Abruptio Placentae, Adult, Aspirin, Drug Therapy, Combination, Female, Humans, Pre-Eclampsia, Pregnancy, Enoxaparin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Enoxaparin and Aspirin Compared With Aspirin Alone to Prevent Placenta-Mediated Pregnancy Complications: A Randomized Controlled Trial. https://app.cochat.ai/papers/10.1097/aog.0000000000001673
The paper
Haddad, B., Winer, N., Chitrit, Y., Houfflin-Debarge, V., Chauleur, C., Bages, K., Tsatsaris, V., Benachi, A., Bretelle, F., Gris, J.-C., Bastuji-Garin, S., & for the Heparin-Preeclampsia (HEPEPE) Trial Investigators. (2016). Enoxaparin and Aspirin Compared With Aspirin Alone to Prevent Placenta-Mediated Pregnancy Complications: A Randomized Controlled Trial. Obstetrics & Gynecology. https://doi.org/10.1097/aog.0000000000001673

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.